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 Plaques of amyloid β peptide (Aβ) are a hallmark trait of Alzheimer’s disease (AD). However, 
the precise role of Aβ aggregates is not well understood. Recent studies have identified that naturally 
occurring N-terminal truncation and pyroglutamylation of Aβ significantly increases its neurotoxicity by 
an unknown mechanism. Content of pyroglutamylated Aβ (pE-Aβ) in AD brains has been shown to 
reach up to 50% of total Aβ. Modified pE-Aβ co-aggregates with Aβ by a seeding mechanism and forms 
structurally distinct and highly toxic oligomers. We studied structural transitions of the full-length Aβ1-
42, its pyroglutamylated form AβpE3-42, their 9:1 (Aβ1-42/AβpE3-42) and 1:1 molar combinations. 
 Transmission electron microscopy was used to directly visualize the fibrils of the samples in a 
buffer mimicking physiological environment. Atomic force microscopy measurements were done to 
determine rate of second nucleation events in fibrils. Thioflavin-T fluorescence indicated that low ionic 
strength suppressed the aggregation of AβpE3-42 but promoted that of Aβ1-42, suggesting different paths of 
fibrillogenesis of unmodified Aβ and pE- Aβ. Interestingly, AβpE3-42 at only 10% significantly facilitated 
the fibrillization of Aβ1-42 at near-physiological ionic strength but had little effect at low salt. 
 Circular dichroism and Fourier transform infrared (FTIR) spectroscopy were used to characterize 
the structural transitions during fibrillogenesis. In aqueous buffer, both unmodified Aβ and pE-Aβ 
peptides adopted parallel intermolecular β-structure. Interestingly, AβpE3-42 contained lower β-sheet 
content than 13C-Aβ1-42, while retaining significantly larger fractions of α-helical and turn structures. 
Structural details of Aβ and pE-Aβ combinations were unveiled by isotope-edited FTIR spectroscopy, 
using 13C-labeled Aβ1-42 and unlabeled AβpE3-42. When exposed to environmental humidity, AβpE3-42 not 
only maintained an increased fraction of α-helix but also was able to reverse 13C-Aβ1-42 β-sheet structure. 
These data provide a novel structural mechanism for pE-Aβ hypertoxicity; pE-Aβ undergoes faster 
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nucleation due to its increased hydrophobicity, thus promoting formation of smaller, hypertoxic 
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CHAPTER ONE: INTRODUCTION 
 
 Alzheimer’s disease (AD) affects more than 35 million people worldwide, with 5.5 
million of those in the United States.1 Plaques of amyloid β (Aβ) peptide are a hallmark trait 
of AD. However, the precise role of Aβ aggregates in AD is not well understood. The 
amyloid cascade hypothesis proposed that extracellular aggregates (plaques) were responsible 
for the onset of AD.2, 3 However, recent data identify soluble Aβ oligomers as neurotoxic 
agents, and show that insoluble, fibrillar aggregates are poorly correlated to brain atrophy.4-10 
Naturally, truncated and pyroglutamylated (pE-Aβ) peptides, such as the pyroglutamylated   
40 amino acids long Aβ (AβpE3-42), have been shown to aggregate at increased rates.11-13 
Recent studies have identified that pyroglutamylation of Aβ significantly increases its 
neurotoxicity even at low fractions. 14, 15 Interestingly, AβpE3-42 has been shown to be highly 
toxic to cultured neurons at the sub-micromolar range and at ≤5% of total Aβ protein.15 These 
data suggest that increased toxicity of AβpE3-42 is through a prion like mechanism. The 
structural nature of the differences in toxicity remains unknown and was explored in this 
work.  The main objective of this project is to gain insight into the molecular mechanism of 
altered fibrillogenesis of Aβ1−42, by studying the aggregation kinetics and accompanying 
structural changes in its pyroglutamylated form AβpE3-42, their 9:1 (AβpE3-42,Aβ1-42), and 1:1 
molar combinations. Our data suggest that under certain conditions AβpE3-42 resists 
fibrillogenesis and inhibits cross-β structure formation of Aβ1-42. This implies that the higher 
AβpE3-42 toxicity may be related to its propensity to form low molecular oligomers. We show 
data collected using a plethora of biophysical techniques, which give new insights into Aβ 
behavior under physiologically relevant conditions.  
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Discovery Of Alzheimer’s Disease 
 
The neurological ailment AD is named after German neuropathologist and clinician 
Aloysius Alzheimer.16 After receiving his medical degree at the University of Wuzbürg  in 
Lower Fraconia, Germany. He was hired at the Municipal Asylum for the Insane and 
Epileptic in Frankfurt.16 This is where he received a patient in which he first identified the 
disease that bears his name. 16 In 1901 a woman called Auguste Deter was admitted to the 
hospital and examined by Alzheimer and was found to show a wide array of symptoms such 
as reduced memory, paranoia and unpredictable behavior.17 A colleague of Alzheimer, Emil 
Kraepelin, published in 1910, the 8th edition of his clinical psychiatry textbook in which the 
term Alzheimer’s disease was born.17  
What Alzheimer first observed in the cerebral cortex of August Deter’s brain is 
probably Aβ peptide aggregates. This peptide is suspected to be a protagonist in the onset 
and development of AD. The Aβ peptide is found in AD brains   and forms large 
extracellular aggregates called amyloid plaques. The identification of the Aβ led to the 
study of the disease at a biophysical and biochemical level. Nearly a century after 
Alzheimer’s discovery and initial studies there is no clear established mechanism for the 
etiology of AD.18 Nonetheless, there has been some modification of the amyloid cascade 
hypothesis over the years; current research is shifting towards the toxicity of small soluble 




Identification of The Amyloid β Peptide And Its Pyroglutamated Form 
 
The Aβ peptide has been primarily focused on the study of Alzheimer’s disease 
since it was first identified. This peptide is a cleavage product after β-secretase and γ-
secretase act on the Amyloid precursor protein (APP).22 The most abundant amyloid 
peptides range from 39 to 42 residues long.23 The 40 residue amyloid peptide (Aβ1-40) and 
Aβ1-42 have been the most extensively studied. However, pE-Aβ  such as AβpE3-42 have 
received much attention in recent years since its first discovery in 1985.24 Both Aβ1-42 and 
AβpE3-42 have been shown to form micron long cross β-sheet fibrils when incubated in 
aqueous buffer.25-28 Additionally, there is evidence showing that incubation conditions 
and presence of seeding species affect final fibril morphology.28 Previously, fibrillar 
plaques were thought to have a high correlation with cell toxicity and death.2, 3 Recent 
attention is focused on oligomeric species and not fibrils as being the toxic entities.  
 Determination of the etiology and treatment of AD has increased in complexity since 
the discovery of post-translationally modified pE-Aβ. Their production occurs when the first 
two amino acids are truncated by aminopeptidases and glutamate at position three is 
cyclized by Glutaminyl Cyclase.14 The loss of two charges increases hydrophobicity and has 
been shown to cause more rapid aggregation.29  Even though pE-Aβ have been shown to 
aggregate at faster rates compared to their unmodified forms, some data shows it to have an 
inhibitory effect on peptide fibrillization.30 Indeed, there exists data showing that Aβ1-42 
aggregates faster than AβpE3-42. 31 The percentage of AβpE3-x has been reported to vary from a 
few % to more than 50% of total Aβ.32, 33 It has been suggested that Aβ toxicity depends on 
peptide ratio and not total Aβ amount.34 
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Evolution Of The Amyloid Cascade Hypothesis 
 
The amyloid cascade hypothesis originally pointed at insoluble extracellular aggregates 
as the toxic species in AD.  Genetic evidence shows a link between a mutation in APP and 
presenilin and higher risk of developing AD.35-38 These mutations lead to familial 
Alzheimer’s disease (fAD). Additionally, these mutations are thought to increase the risk of 
AD by increasing Aβ peptide production. 39 These data suggest a strong link between the 
onset of AD and higher concentrations of Aβ peptides.   
The formation of neurofibrillary tangles made of Tau protein has been shown to be 
neurotoxic.40  It has been shown that cultured rat neurons treated with oligomeric Aβ species, 
displayed translocation from Tau rich axons to dendrites.41 Alternatively, some studies have 
identified plaques in brains that do not show pathological Alzheimer’s symptoms.42 In 
addition, oligomeric species have been found at higher concentration in human brains with 
cognitive impairment.43  Finally, it has been suggested that toxicity is detected before plaques 
are observed in the brain.5  In fact, there has been data showing that Aβ  fibrillar seeds and 
monomers may be benign or even protective.44, 45  
These data have led to the modification of the amyloid cascade hypothesis to one in 
which soluble oligomers like dimers, trimers and dodecamers are the cytotoxic entities.44, 46-49 
Soluble oligomers have been shown to act through several mechanisms such as endoplasmic 
reticulum (ER) calcium leakage, synaptic loss and have been shown to interact with cell 
membrane receptors.50, 51  
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Experimental Pitfalls In Previous Aβ Study 
 
Concerns have been raised that non physiological experimental conditions of 
Aβ studies might have led  to incorrect conclusions about its toxic effect.20 Also, that 
Aβ peptides have been thought to be associated to other cellular components and hence some 
studies are too narrow in breadth.20Non-physiological conditions such as high ionic strength, 
acidic and alkaline buffers have been used to determine Aβ behavior. 11, 31 These strategies 
have given some insight into the fibrillization kinetics of Aβ. Unfortunately, results from a 
highly varied degree of conditions have also been very diverse. Additionally, increased 
calcium concentrations have been shown to increase fibrillization rates of Aβ peptides.52  A 
group of chaperones identified as “Aβ pathological chaperones” of which Acetylcholinestrase 
is an example, have been identified.53 Acetylcholinesterase is thought to aid and increase 
Aβ fibrillization.53  Therefore, it is important to provide a more in depth structural and 
functional description of Aβ peptides.  
 The aim of this work was to study the effect AβpE3-42 on Aβ1-42 structure and 
aggregation. By doing this in varying buffer conditions we are able to determine the role of 
ionic strength on Aβ conformation and fibrillization kinetics. This work also aimed at 
determining several intermediates during the oligomerization process. Different structural 
intermediates can help shed light on the structural effects of AβpE3-42 on Aβ1-42 and its role in 
AD. It is important to emphasize that aggregation and fibrillization kinetics are of high 
importance in the elucidation of the role of Aβ in AD.  Structural characteristics of 
oligomeric species will probably pave the way to  new AD  mechanistic understanding. 
Presently, these “pathological conformations”  remain elusive.54 
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CHAPTER TWO: LITERATURE REVIEW  
 
 The interdisciplinary nature of this project required a careful analysis of a large pool 
of previously published results. AD research is primarily focused on the study of Aβ peptides 
and the role they play in disease pathology. The molecular aspect of Aβ peptides was 
researched to gain insight on the current knowledge of their cytotoxic effect on the brain. 
This information was essential to determine cytotoxicity differences between 
pyroglutamylated and unmodified Aβ. The ratio of modified to unmodified Aβ peptides was 
an important piece of data, required for effective design of experimental procedures.  
 This project employed several techniques which include: i) Fourier transform infrared 
(FTIR) spectroscopy ii) circular dichroism (CD) iii) aromatic amino acid fluorescence iv) 
atomic force microscopy (AFM) v) Thioflavin T (ThT) fluorescence assay and vi) 
transmission electron microscopy (TEM).  
 Initially our strategy was to determine AβpE3-42 and Aβ1-42 secondary structure in dry, 
aqueous buffer and organic solvent conditions.  Indeed, many structural studies have been 
done on amyloid peptides such as Aβ1-40. 27 Solid-state nuclear magnetic resonance (ssNMR) 
elucidated the amyloid cross β-sheet structure.27 These β-sheet rich motifs have been 
identified  in Aβ peptides,55, 56and in other proteins related to a variety of  diseases57, such as 







Alzheimer’s Disease Etiology 
 
 Aβ peptides are cleavage products from the amyloid precursor protein.1 Enzymes 
called β-secretase and γ-secretase cleave Aβ from APP as mentioned above. Mutations in γ-
secretase, the active portion of presenilin-1,62  are associated with fAD, which accounts for  
<5% of total AD case.63 It is interesting to note that even though AD was discovered nearly 
100 ago there is still no treatments that reverse or stop cognitive decline. There have been 
many attempts to identify AD causing factors.  Apolipoportein E (ApoE), specifically the ε4 
allele has been associated with an increased risk of AD when compared to ε2 and ε3 
alleles.64ApoE has many roles. It has strong binding affinity for Aβ and cholesterol.65, 66 This 
can lead to a higher accumulation of Aβ in the intracellular space and also could starve the 
cell of cholesterol. Certain diet tendencies have also been associated to AD.67 Some studies 
have suggested that the intake of omega-3 fatty acids reduces the risk of AD.68, 69 Moreover, 
Tau proteins are related to neurofibrillary tangles (NFT’s) which are suspected of having a 
pathological role in AD.  Tau proteins are microtubule associated proteins that serve to 
stabilize microtubules. NFT’s form when highly phosphorylated tau aggregates.70 Other data 
suggest toxicity of tau oligomers.71  
 AD is associated with advanced age. Specifically, vascular changes and pathologies 
are associated with aging and AD.  Cerebral amyloid angiopathy (CAA), where Aβ peptides 
are deposited on leptomeningeal and cortical blood vessel walls are associated with aging, 
AD and other pathological states of vasculature.72  Calcium homeostasis dysregulation has 
also been extensively investigated as having a causative role in AD.73-75 Indeed, data has 
shown that physiologically relevant calcium concentrations increase Aβ1-42 fibrillization 
8 
 
 rate.52 Pore formation capacity on cell plasma membranes of Aβ peptides has also been 
linked to calcium homeostasis dysregulation 76, 77  
 Several mechanisms have been proposed to explain how Aβ peptides elevate calcium 
levels by pore formation. Neurotoxic species of Aβ have structural and functional homology 
with pore forming bacterial toxins.78 The conformation specific antibody A11 binds 
selectively to Aβ1-42 oligomers as well as perforin and α-hemolysin, indicating a similarity in 
oligomeric structure of pore forming and amyloid peptides.78 Pores are thought to form on the 
cell membrane and thus increase influx of calcium into the cytoplasm, thereby rendering the 
neurons susceptible to excitotoxicity. 73 Other models show pores forming on the ER surface, 
leading to an increase in calcium concentration in the cytosol. The ER pathway suggest that 
intracellular Aβ binds to ryanodine receptors, followed by abnormal activation of 
phospholipase C,  which  triggers further Phosphatidylinositol (3,4,5)-triphosphate  (PIP3)-
mediated ER calcium  release, leading to apoptotic cell death.50 In other experiments, Aβ1-42 
has been shown to promote production of ryanodine receptor mRNA and protein in mice 
primary cortical neurons.79 Additionally, Aβ have been shown to cause a calcium dependent 
cytotoxic effect on rat brain endothelial cells.80  
 Some cell membrane receptors have been shown to bind Aβ1-42. Oligomeric Aβ1-42 
has a high binding affinity for the leukocyte immunoglobulin like receptor B (LilrB2).51 Mice 
experiments confirmed that Aβ1-42 interacts with PirB, a LilrB2 homolog, and diminishes 
ocular dominance plasticity.51 Aβ soluble oligomers have also been shown to bind with high 
affinity to lipid anchored cellular prion protein (PrPc) on the postsynaptic density. 81The 
mGluR5 transmembrane receptor links PrPc to an intracellular kinase called Fyn; downstream 
effects promote dendritic loss.81 
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 Phosphatidylserine exposure increases Aβ ability to associate to the cell membrane. 82 
It is possible that age related mitochondrial defects increase phosphatidylserine content on the 
outer cell membrane. Decreased cytosolic adenosine triphosphate (ATP) and the presence of 
cells in G1 stage had positive correlation with Aβ binding and an increased cytosolic calcium 
concentration. 82 Moreover, data has shown that Aβ1-42 cytotoxicity is affected by membrane 
cholesterol concentration.83-85  Some experiments show that cholesterol deficient plasma 
membranes are more susceptible to toxic effect of Aβ.83 While others state that increased 
cholesterol content facilitates Aβ toxicity.86  
 Mitochondria impairments have been linked to AD.87, 88  With increased age there is 
an increase in mitochondria oxidative stress.89 Reactive oxygen species (ROS) generated 
from mitochondria increase Aβ formation. 89 Interestingly, Aβ has been found in 
mitochondria of AD in both monomeric and oligomeric forms.89 This suggests a role of Aβ in 
mitochondrial related defects in AD .  The electron transport chain is involved in producing 
the cell’s energy in form of ATP. Oxygen is the final electron acceptor and is subsequently 
reduced to water. In this process ROS can oxidize lipids, mitochondrial DNA, and proteins 
which in turn increase mitochondrial degeneration.90 Excessive mitochondrial fission has 
been observed in AD, this may lead to dysfunction in mitochondria and thus impaired 
neurons. Intraneuronal Aβ has been show to bind to fission related dynamin related protein 
(Drp1).91 Mitochondrial fission genes expressing Drp1 and fission 1 (Fis1) have been shown 
to be upregulatd in AD brains.91 This probably leads to an imbalance in mitochondrial 




Aβ And pEAβ  Comparison 
 
 With the discovery of pyroglutamylated amyloid peptides arose a need to determine 
its cytotoxic effect and shed light on its role in AD. After cleavage from APP, the N-terminal 
aspartate and alanine are nonspecifically truncated by intracellular aminopeptidases, followed 
by cyclization of glutamates at position 3. Loss of two charges (the N-terminal primary amine 
and the Glu3 side chain carboxyl) increases hydrophobicity; faster aggregation kinetics have 
been observed for AβpE3-42. Concentrations of pyroglutamylated Aβ in the AD brain have 
been shown to reach 50% of total Aβ. 
 Data suggest that the ratio of Aβ and pEAβ has a significant effect on cytotoxicity 
and aggregation kinetics.25, 30 A literature search of fibrillization studies resulted in 
conflicting data. Some reports showed pEAβ to aggregate faster than Aβ1−42,11, 30, 92 while 
others showed the opposite 31 Importantly, one group has reported that AβpE3-42 inhibits 
Aβ1−42 fibrillization and cross β-sheet formation by TEM studies.30 Pyroglutamylation of Aβ 
increases resistance to aminopeptidases and astrocyte induced degradation.25 Even though 
there has been extensive studies comparing Aβ1-42 and AβpE3-42, an understanding in unique 
features in the structural effect of AβpE3-42 on Aβ1-42 has not been reached. Our work aims to 




Methodology literature review 
 
 This project applied a wide array of biophysical techniques. Protocols will be 
discussed in the methods chapter and only a brief overview of searched literature is provided 
below. We followed a careful series of steps to elucidate the fibrillization kinetics, peptide 
secondary structure and fibril morphology. The effect of ionic strength on structure and 
fibrillization was also studied. ThT binding assays probed fibril formation in solution. ThT 
has been shown to fluoresce in the visible range when bound to cross β-sheet structure 
formed by fibrils.93-95 
 Previously published data helped us develop optimal ThT concentrations. We 
employed CD, FTIR, and isotope edited FTIR  to investigate secondary structure and 
interactions between Aβ1-42 and AβpE3-42. Interpretation of CD spectra was aided by searching 
previous published protocols.96 Positions of secondary structure components in the infrared 
Amide I region were researched.97  Importantly, the effect of 13C isotope presence in peptide 
was reviewed to help determine shift in Amide I.98, 99  
 Fibril morphology was probed by TEM and AFM. Preparation of fibrils and amyloid 
aggregates was researched.28, 100-103 Optimal buffer conditions were also determined. TEM 
and AFM substrates were carefully selected for sample preparation. We used graphene coated 
grids for TEM which provide superior resolution of amyloid peptides.104 Mica was the 
substrate used for AFM.   
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CHAPTER THREE: RESEARCH METHODS 
 
 This work aims to determine the secondary structure and the strength of association 
between AβpE3-42 and Aβ1-42 in dry, aqueous buffer and intermediate conformations. Isotope 
edited FTIR is an ideal approach for this purpose. Subsequently, the effect of AβpE3-42 on 
Aβ1-42 fibril formation determined by ThT will be investigated. Finally, fibril morphology 
will be probed by TEM and AFM measurements. Our experimental samples consisted of Aβ1-
42, AβpE3-42, their 9:1 (Aβ1-42/AβpE3-42) and their 1:1 molar combinations. Aβ peptides adopt a 
α-helical conformation in HFIP. 105, 106 Moreover, fluorinated alcohols have been shown to 
break up aggregates and promote monomeric state of Aβ peptides.105, 106 CD proved to be 
optimal when estimating peptide secondary structure in HFIP. FTIR showed secondary 
structure of desiccated peptides and in bulk aqueous buffer. By 13C uniform labeling of Aβ1-42 
we are able to dissect peptide mixtures when this peptides is combined with unlabeled AβpE3-
42.   This is achieved since 13C labeled peptides show a downshift of the Amide I band of  ~45 
cm-1. 
 By following ThT fluorescence we were able to study fibril formation from a 
monomeric state. Our experiments were done under two buffer conditions i) 50 mM 
phosphate and 50 mM sodium chloride, at pH 7.2  and ii) 10 mM phosphate at pH 7.2. These 
buffer conditions were selected to determine the effect of ionic strength on peptide structure 
and fibrillization kinetics. TEM and AFM were performed to determine characteristic 
differences between fibrils and to identify second nucleation sites. Combining data from 
these techniques permitted the careful study of Aβ1-42 and AβpE3-42 behavior under varying 
conditions.  Below there is a detailed description of the conditions and procedures used to 
collect and analyze the data presented in this project.  
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Secondary Structure And Fibrillization Kinetics Studies 
 
 Secondary structure of peptides was determined using CD and FTIR. Peptides 
secondary structure is of upmost importance in determining protein behavior, interaction with 
their surroundings, and function. Initially, peptides were dissolved in HFIP to disperse 
previously formed aggregates. To remove HFIP, samples were gently dried with a stream of 
nitrogen and vacuum desiccated for 15 minutes. The CD measurements were performed on 
Aβ peptides using 4mm quartz cuvettes and measured using a Jasco J-810 spectropolarimeter 
with a fluorescence attachment (Tokyo, Japan). ThT binding assay was taken simultaneously 
with CD. Both buffer conditions mentioned above were used for comparing the effect of salt 
on Aβ behavior. 
 CD was measured in HFIP dissolved peptides using a 0.5 mm cylindrical cuvette. 
Measurements in buffers were performed on 50 µM solutions over a time span of 24 hours, 
while gently stirring. CD spectra were measured ranging from 180 nm to 330 nm. ThT was 
excited at 440 nm and emission was recorded from 430 nm to 540 nm. Maximum intensity 
vs. time graphs were plotted. In the case for ThT the emission maximum was determined to 
be 483 nm and was baseline corrected by subtraction of the signal at 540 nm.  
  Further structural assessment was achieved by isotope edited FTIR. The spectra were 
measured on a Vector-22 FTIR spectrometer (Bruker Optics, Billerica, MA, USA) equipped 
with a liquid nitrogen-cooled Hg-Cd-Te detector, at 2 cm-1 nominal resolution. Measurements 
were taken using two peptide stock concentrations in HFIP. First, 13C labeled Aβ1-42 and 
AβpE3-42 were dissolved at 200 µM in HFIP. Forty  µL of each peptide and their 9:1 and 1:1 
mixtures were placed on a CaF2 FTIR window and then desiccated for 15 minutes to remove 
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residual HFIP. Transmission spectra in buffer were taken using 1000 consecutive scans while 
dry samples were taken using 500 scans and absorption was calculated using appropriate 
reference transmission spectra. 
 Samples containing peptides by themselves and in mixture were exposed to air to 
determine the effect of moisture on the secondary structure. Presence of increased moisture 
was confirmed by the increase in the H2O stretching bands near 3,200 cm-1.97 
 Subsequently peptide stocks were made at 50 µM in HFIP. Secondary structure for 
these samples was probed under two different bulk buffer conditions mentioned above. 
Eighty µL of peptide solution were dried and desiccated as mentioned above. After 
measuring dry spectra 80 µL of bulk D2O buffers were added and samples were sandwiched 
between 2 CaF2 windows using a 50 µm Teflon spacer, and measured using 1000 scans for 
several hours to observe changes in secondary structure. The pD of D2O buffers was 6.8 
corresponding to pH 7.2. D2O is used instead of H2O because H2O absorbs in the amide I 
region and obscures the protein signal.107 Reference spectra for both buffers were taken in a 
similar fashion without the presence of peptide for calculation of absorption spectra.   
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Fibril Morphology by TEM and AFM 
 
 TEM and AFM measurements were performed to probe Aβ fibril and aggregate 
morphology. For TEM, peptides were dissolved in HFIP and dried as described above. Dried 
peptide film was resuspended to 50 µM using 50 mM phosphate with 50 mM NaCl buffer at 
pH 7.2. Samples were stirred at 37oC for 24 hours. Five µL of peptide preparations were 
placed on graphene coated grids. After 5 minutes excess water was wicked off. Samples were 
washed twice with diH2O, and were negatively stained with 3% uranyl acetate. After 
washing, samples were measured using a JEOL TEM-1011 (Tokyo, Japan) operated at 80kV. 
Data was collected at several time points 2,4,12 and 24 hours to determine aggregation and 
fibrillization states of peptides.  
 AFM sample preparation was similar to TEM. After 24-hour incubation, 25 µL of 
fibril preparation was placed on freshly cleaved mica. Mica was incubated for 24 hours to let 
fibrils adsorb to the substrate. Then mica was washed with ultra-pure water and vacuum 
desiccated for 15 minutes. Measurements were taken using a Dimension 5000 Atomic Force 
Microscope system (Digital instruments, Santa Barbara, Ca, USA) equipped with a silicon tip 
with a length of 160 mm, thickness of 4.6 mm, and width 45mm.  Amplitude and height 
profiles helped elucidate fibril morphological characteristics.  
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CHAPTER FOUR: RESULTS 
 
 In this work we examined Aβ1-42, AβpE3-42, their 9:1 (Aβ1-42/AβpE3-42) and 1:1 molar 
combinations. Previous data have shown that Aβ oligomeric mixtures  containing low % of 
AβpE3-42, have increased neurotoxicity  when compared to Aβ1-42 alone, and are structurally 
distinct.15 This suggests that differences in toxicity levels are related to Aβ oligomer 
secondary structure. We hypothesized that AβpE3-42 and Aβ1-42 have strong intermolecular 
interactions in buffer.   
 Both Aβ1-42 and AβpE3-42 aggregate into amyloid fibrils. Some disagreements have 
arisen concerning which has increased fibrillization rate. Some data show that Aβ1-42 
fibrillizes faster than AβpE3-42,31 while others point to the opposite.11 Aggregation pathways 
are of significance, since intermediate oligomeric species and not mature amyloid fibrils are 
thought to be the neurotoxic entities in AD.108 Some data suggest that mature fibrils might be 
neuroprotective, by sequestration of monomers, and thus inhibition of oligomer formation.109 
In our studies we focused on the effect of salt concentrations on Aβ structure and 
fibrillization. Based on these data we hypothesized that varying buffer conditions promote 
diverse trends in aggregation.    
  Data from this project resulted in significant advancements in the understanding of 
Aβ peptides, which can be divided into two main ideas. AβpE3-42 affects Aβ1-42 structure and 
fibrillization kinetics when combined at disease relevant ratios. Secondly, ionic strength plays 




 Strong solvents such as HFIP have been reported to promote monomeric state of Aβ 
peptides.110 In HFIP Aβ1-42 has been shown to be in α-helical and unordered 
conformations.111 Peptide samples in α-helical conformation show negative minima around 
222 nm and 208 nm.112 Unordered structures are characterized by a strong negative band near 
200 nm.112  CD spectra confirmed α-helical and unordered secondary structures for all 
samples in HFIP (fig. 1 a). Additionally, AβpE3-42 shows a reduced ratio of ellipticities, 
θ208/θ222, this indicates a more flexible, unordered α-helix.113  The α-helical conformation is 
present after desiccation as seen in (fig. 1 b). This permits us to follow fibrillization from 
initial non-aggregated states.  
 Presence of bulk aqueous buffer promotes structural changes on Aβ samples and their 
combinations (fig. 1 c).Both Aβ1-42 and the 9:1 combination show a negative band around 
218, corresponding to β-sheet structure.96  Wider and broader negative bands for AβpE3-42 and 
the 1:1 combination suggest a combination of α-helix with β-sheet.114 Interestingly, a higher 
molar concentration of AβpE3-42  reduces β-sheet propensity and is similar to AβpE3-42 by itself, 
as shown by the 1:1 combination spectrum. Our data show that Aβ1-42 and AβpE3-42 contain 
distinct structural features in buffer. Additionally, at equimolar concentrations AβpE3-42 is able 
to transmit structural features to Aβ1-42, and promote a more helical conformation, by 




Figure 1. CD spectra of Aβ1-42 (green), AβpE3-42 ( light blue), 9:1 Aβ1-42/AβpE3-42  (blue) and 
1:1 (red) peptide  combinations in HFIP (A), desiccated (B), and bulk buffer (C) conditions. 
Buffer composition is 10 mM Na,K-phosphate at pH 7.2. 
 
 For further elucidation of unique structural features of individual and mixed Aβ 
peptides, isotope edited FTIR was employed. Uniform isotope enrichment of the backbone 
carbons of Aβ1-42 produces a spectral downshift of ~45 cm-1. In buffer conditions 13C-Aβ1-42 
shows prominent intermolecular β-sheet structure as evidenced by a peak around 1585 cm-1 
(fig. 2 blue line).  In bulk buffer conditions AβpE3-42 shows absorbance around 1628 cm-1 
corresponding to β-sheet (fig. 2 red line). Interestingly, the pyroglutamylated peptide also 
shows significant absorbance ranging from 1650 to 1680 cm-1.  This indicates that AβpE3-42 is 
in partial α-helical conformation, while Aβ1-42 is mostly β-sheet. The amide II provides 
additional structural information. Open, or solvent accessible tertiary structures  undergo 
rapid hydrogen/deuterium exchange. This results in reduction of the amide II band at ~1540 
cm-1.115 Data from figure 2 shows that 13C-Aβ1-42 retains significant absorption at the amide II 
band. This suggests that 13C-Aβ1-42 forms tight tertiary structure.  Tight intermolecular β-
sheets are indicative of fibril cross β-sheet structure.116, 117 Conversely, AβpE3-42 forms an 
open solvent accessible structure, shown by a loss of amide II absorption. These data agree 
with the CD data  in figure 1. Unmodified Aβ1-42 forms tight intermolecular β-sheet, while 
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AβpE3-42 forms an open solvent accessible partially α-helical structure. These data suggest 
that partial α-helical structures and not fibril cross β-sheet are the hypertoxic species in AD.  
 
Figure 2. FTIR spectra AβpE3-42  (red line) and 13C-Aβ1-42 (blue line) in 10 mM Na,K 
Phosphate buffer (pD 7.2). Peptide concentration is 100 µM. 
  
  Further FTIR measurements were performed at 50 µM, on desiccated peptide 
samples. Presence of α-helical conformation after HFIP desiccation was probed. Spectra for 
Aβ1-42 and AβpE3-42 show predominant α-helical peak around 1658 cm-1 as shown in (fig. 3 
a,b). Spectra of both 9:1 (13C-Aβ1-42/AβpE3-42) (fig. 3 c) and 1:1 (13C-Aβ1-42/AβpE3-42) (fig. 3 
d) show prominent α-helical component belonging to AβpE3-42 near 1660 cm-1. In the 9:1 
combination the peak at 1618 cm-1 shows the α-helical structure of isotope enriched 13C-Aβ1-
42. Conversely, the absorption profile of the sample with equimolar peptide concentrations 
shows a peak at around 1604 cm-1. This peak is probably irregular secondary structure of 13C-
Aβ1-42. This low frequency component difference in the combination measurements led us to 
explore the possibility that hydration levels or varying peptide ratios exerted an effect on 
amyloid secondary structure. Aβ peptides absorb atmospheric humidity, which results in H2O 
stretching and increase in intensity at  ~3270 cm-1.97 Humidity exposure of combinations 
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helped determine if conformational changes were caused by peptide interactions and/or 
exposure to moisture. As shown in  (fig. 4) Aβ1-42 contains the highest amount of humidity 
followed by the 1:1 combination; AβpE3-42 and  the 9:1 contain the  lowest and a very similar 
amount of humidity. The 1:1 combination and Aβ1-42 show different secondary structure 
components while having similar amounts of humidity. These data motivated experiments 
where the effect of AβpE3-42 on Aβ1-42 structure was investigated in bulk buffer conditions at 
10% and 50% AβpE3-42. 
 
Figure 3. FTIR of desiccated Aβ1-42 (A), AβpE3-42 (B), 9:1 (13C-Aβ1-42/AβpE3-42) (C), and 1:1 
(13C-Aβ1-42/AβpE3-42)  (D) molar combinations. Peptide dried from a 50 µM stock. 
  
  




Figure 4. H2O stretching mode of Aβ1-42 (green), AβpE3-42 (light blue), their 9:1 (blue) and 1:1 
(red) molar combinations under desiccated conditions. 
  
 Interpretation of previously published toxicity data led us to hypothesize that AβpE3-42 
interacts strongly with Aβ1-42. Dot blot experiments showed that oligomers of  Aβ1-42 and 
AβpE3-42 combinations are in distinct structural conformations, when compared to single 
peptide oligomers.15 We hypothesized that combining Aβ1-42 and AβpE3-42 affects their 
secondary structure. FTIR was employed pursuing two specific goals. First, determine that 
AβpE3-42 and 13C-Aβ1-42 have close intermolecular interactions. Secondly, probe the structural 
effects of the pyroglutamylated peptide on the unmodified Aβ. 
 We studied the effect of AβpE3-42 at 10% and 50% total peptide content. To determine 
the presence of intermolecular interactions we compared the mixture spectra to the weighted 
average sum spectra of the peptides by themselves.  At 10% AβpE3-42 the β-sheet peak at 1585 
for 13C-Aβ1-42 is upshifted by 3 cm-1, and by 10 cm-1 at equimolar concentrations (fig. 5 a). 
The β-sheet component around 1626 cm-1 for AβpE3-42 upshifts by 10 and by 4 cm-1 when at 
10% and 50% total peptide, respectively. This shows strong vibrational coupling between 
both species, implying that AβpE3-42 and Aβ1-42 form mixed β-sheet structures with strong 
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intermolecular interactions. Additionally, at equimolar concentrations the averaged sum 
shows significantly larger turn component (fig. 5 b), evidenced by increase absorption near 
1671 cm-1, when compared to the mixture spectra.   
 Transition of Aβ peptides from α-helical when dry to β-sheet when exposed to buffer 
led us to hypothesize that exposure to environmental humidity would have an effect of peptide 
secondary structure. These data could shed light on intermediate conformations preceding  
fibrillar cross β-sheet structure. Structural effects were probed by exposing 9:1 (13C-Aβ1-
42/AβpE3-42)   and 1:1 molar combinations to environmental humidity for established periods of 
time. And infrared measurements were collected.  
 The initial 9:1 combination spectra taken after 10 minutes of incubation is dominated 
by the spectral features of the 13C-Aβ1-42 i.e. α-helical at 1617 cm-1  and β-sheet component at 
1592 cm-1 (fig. 6 a).  The peak at 1655 cm-1 represents the α-helical component of the AβpE3-
42. The 20 minute spectrum shows a α-to-β transition of the 13CAβ1-42 as shown by blue line. 
Strikingly, the β-sheet content in the 20 minutes incubated sample is lower than expected 
without the interaction of the peptides ( the weighted sum of the individual spectra incubated 
for 15 minutes represented by the green line). This data suggest that AβpE3-42 slows down 





Figure 5. FTIR spectra of 13CAβ1−42 and AβpE3-42 combined at 9:1 (A) and 1:1 (B) molar 
ratios, incubated in a D2O-based 10 mM Na,K phosphate buffer (pD 7.2) for 2 h, at a total 
peptide concentration of 100 μM. Blue and green lines are the experimental spectra obtained 
on the two peptides combined in one sample and the weighted sums of individual spectra, 
respectively. The weighted sums were obtained as A = ΣfiAi, where fi is the molar fraction 
and Ai is the absorbance spectrum of each individual peptide measured separately. 
 
 Moreover, at a 1:1 combination, AβpE3-42 reverses fibrillization evidenced by the 
reduction of the 13CAβ1-42 β-sheet signal at 1595 cm-1 (fig. 6 b green line). The sample 
exposed to environmental humidity for twenty minutes (fig. 6 b blue line) shows strong 
absorption near 1658 cm-1, corresponding to the α-helical component of AβpE3-42 with some 
contribution from the turn components of the unmodified peptide. Most importantly, there is 
no α-helix to β-sheet conversion of the Aβ1-42 when combined with AβpE3-42 at equimolar 
concentrations, as shown by similar signal intensity at 1617 cm-1 after 10 and 20 minutes of 
incubation.  
 In fact, β-sheet present at 10 minutes is reversed. Our data imply that at 10% AβpE3-42 
the fibrillization process is slowed down. When AβpE3-42 and 13CAβ1-42 are incubated at equal 
ratios the fibrillization process is completely inhibited, and reversible, while α-helical 





Figure 6. FTIR spectra of humidified Aβ at a 9:1 (13C-Aβ1-42/AβpE3-42) (A) and  1:1 (13C-Aβ1-
42/AβpE3-42) (B) combinations. Red and blue lines are experimental spectra of desiccated HFIP 
samples followed by exposure to atmosphere for 10 and 20 minutes, respectively. The green 
spectrum is the weighted sum of the spectra of each combination measured individually, 
exposed to the atmosphere for 15 minutes.  
 
  Additionally, strong intermolecular interaction between the peptides is shown by a 
frequency shift of the β-sheet component of 13C-Aβ1-42 from 1588 to 1592 cm-1 for the 9:1 
combination and to 1595 cm-1 for the 1:1 combination. These data suggest that AβpE3-42 might 
shift aggregation pathway to the formation of partial α-helical intermediates by direct 
intermolecular interactions with the unmodified peptide. Continuing from this interesting 
finding, we attempted to determine the structural effect of humidification of the AβpE3-42/13C-
Aβ1-42 combination with  D2O vapor. By exposing a 1:1 Aβ combination we are able to probe 
gradual structural changes that happen in an undetectable time frame when bulk buffer is 
added to dried samples. To achieve this we used a nitrogen tank that blew nitrogen gas 
through four Erlenmeyer flasks that contained D2O heated to a moderately simmering 
temperature followed by delivery of the D2O-saturated gas to the infrared spectrometer 




 While D2O traveled through the instrument chamber FTIR spectra were taken every 
10 minutes.  Thereafter, the sample was left in the instrument chamber without 
humidification for 24 hours. Finally, the CaF2 window containing the sample was left 
exposed to environmental humidity for 3 days. The initial absorption spectra corresponding 
to the desiccated sample with no humidity exposure shows prominent α-helical structure of 
both 13C-Aβ1-42  and AβpE3-42  (fig. 7 black line). This is evidenced by the prominent peak 
near 1657 cm-1 for AβpE3-42  and at 1617 for  13C-Aβ1-42.  Even under desiccated conditions 
there is some β-sheet component, showed by a small shoulder at 1598 cm-1.Exposure to 
humidification by D2O initiates β-sheet formation of the 13C-Aβ1-42 as evidenced by an 
increase in the 1598 cm-1 peak with a decrease in the 1617 cm-1. The AβpE3-42 α-helical 
component decreases while absorbance increases near 1628 cm-1, corresponding to β-sheet 
formation. Strikingly, after humidity was removed from instrument sample chamber and 
purged dry air for 24 hours there was an increase in native β-sheet secondary structure of 
AβpE3-42.  This is evidenced by an increase in intensity of the component at 1639 cm-1 (fig. 7 
blue line). After 3 days of environmental exposure this component approaches a more 
unordered structure by increasing to 1646 cm-1. This data show that the AβpE3-42 has very 




Figure 7. 13C-Aβ1-42 and AβpE3-42 combined at a 1:1 molar ratio desiccated from HFIP (black 
line) and exposed to D2O-saturated nitrogen gas while spectra were taken every 10 minutes 
(decreasing red line darkness). Sample was left in the instrument chamber while purging with 
dry air for 1 day (blue line). Subsequently, sample was exposed to environmental humidity 
for 3 days (light blue line). Total peptide concentration was 50 µM. 
 
 These experiments were conducted with peptides from 50 µM stocks, while samples 
from figure 6 were from 200 µM stocks. Our data show that humidity, Aβ mixture ratio and 
initial stock concentrations could affect peptide behavior and oligomerization pathways, by 







Figure 8. FTIR spectra of 50 µM Aβ1-42 in 50 mM NaCl + 50 mM Na,K-phosphate (pD 7.2) 
(A) and at 10 mM Na,K phosphate (pD 7.2) (B), and AβpE3-42 in 50 mM NaCl + 50 mM 
Na,K-phosphate (pD 7.2) (C) and 10 mM Na,K-phosphate (pD 7.2) (D).  
 
  Previous experiments report that Aβ1-42 aggregates more readily than AβpE3-42.31 
Others report that AβpE3-42 fibrillizes faster.11 This led us to investigate the secondary 
structure of different Aβ peptides and their combinations under both high and low ionic 
strengths, to determine if variations in fibrillization pathways were caused by initial 
secondary structure differences. Additionally, oligomeric structure of Aβ peptide mixtures 







  To determine if the initial secondary structure have unique characteristics we have 
employed FTIR on both Aβ1-42 and AβpE3-42 as shown in figure 8.  Ionic strength plays an 
important role on fibrillization kinetics and both low and high salt conditions were probed in 
these studies. At both salt concentrations Aβ1-42 displays a prominent β-sheet component, 
evidenced by a strong absorption band at ~ 1628 cm-1 (fig. 8 a,b). Interestingly, close to 
physiological salt concentrations (fig. 8 a) Aβ1-42 shows a higher turn to sheet ratio when 
compared to low ionic strength (fig. 8 b), evidenced by a more intense turn component at 
~1671  cm-1.  
 In Both high and low salt concentrations, AβpΕ3−42   shows prominent β-sheet 
signature and a turn component, shown by a strong absorption peak at ~1628 cm-1,  and a 
weaker component at 1671cm-1 (fig. 8 c,d), respectively. Salt concentrations have no effect 
on tertiary structure and compactness of either peptide in aqueous environments as shown by 
constant amide II intensities at ~1540 cm-1. In both cases Aβ1-42 shows a strong Amide II 
band, pointing at a compact tertiary structure. Conversely, AβpE3-42 shows a more solvent 
accessible tertiary structure shown by a lack of absorption in the Amide II region. 
Interestingly, ionic strength has a significant effect on Aβ1−42  secondary structure which 
helps give molecular insight into differences seen in fibrillization rate and final 
aggregate/fibril morphology. Differences in secondary and tertiary structure help explain 








 Similar experiments were conducted on the 9:1 Aβ1-42/AβpE3-42 (13C-Aβ1-42/AβpE3-42)   
and 1:1 combinations. By employing Isotope labeled FTIR distinct structural features of each 
peptide were obtained.  At a 9:1 at both low and high salt concentrations the peptide mixture 
shows strong intermolecular β-sheet evidenced by absorbance at 1590 cm-1 (fig. 9 a,b). This 
peak corresponds to vibrational modes between 13C-Aβ1-42 and AβpE3-42. The component at ~ 
1638 cm-1 is more prominent under high ionic strength conditions and probably belongs to 
the β-sheet component of AβpE3-42. This component represents ~44% of the height of the 
component at ~1590 cm-1 for high salt concentrations and ~32% for low ionic strength 
conditions. These data suggest that higher ionic strength better promotes β-sheet of the 
pyroglutamated form.  
 At equimolar peptide concentrations there are prominent β-sheets peaks at ~1633 cm-1 
for the pyroglutamylated peptide and at ~1596 cm-1 for the hybrid β-sheets. The higher 
frequency for the component under 1600 cm-1 indicates strong 12C-13C vibrational coupling. 
This indicates a larger interaction and hybridization between both labeled and unlabeled 
peptides.  
 Interestingly, variations in salt concentrations affected the tertiary structure of both 
samples. At a 9:1 ratio there is a less compact tertiary structure under low ionic strength as 
shown by the amide II band at ~1540 cm-1 (fig. 9 b). While at a 1:1 ratio lower salt retains 
higher amide II signal and thus shows a more compact and less solvent accessible structure. 
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Figure 9. FTIR spectra of 9:1 50 µM (13C-Aβ1-42/AβpE3-42) in 50 mM NaCl + 50 mM Na,K 
phosphate (pD 7.2) (A) and at 10 mM Na,K phosphate buffers (pD 7.2) (B), and 1:1 (13C-
Aβ1-42/AβpE3-42) 50 mM NaCl + 50 mM Na,K-phosphate (pD 7.2) (C) and at 10 mM Na,K-
phosphate buffers (pD 7.2) (D). 
  
 We were also interested in how AβpE3-42 affects Aβ1-42 peptide fibrillization kinetics. 
Specifically, the role that ionic strength plays in Aβ mixture fibrillization. For this purpose 
we incubated peptide samples with ThT which has been shown to fluoresce in the visible 
range when associated to amyloid fibrils.93 Experiments were performed at 37°C while gently 
stirring. Additionally, two different salt concentrations were used to determine the effect of 
ionic strength on peptide fibrillization kinetics. Experiments were done in aqueous buffer 
containing 10 mM phosphate at pH 7.2 and at 50 mM Na,K-phosphate and 50 mM NaCl at 




 Fibrilization kinetics of Aβ1-42 under two different ionic strength conditions produced 
varying results. This suggests a determining role played by salt in Aβ interactions. A double 
exponential curve fit was used to determine the nucleation and elongation events of Aβ1-42 
(fig 10. black lines). In 10 mM phosphate buffer at pH 7.2 the time constants are τ0 = 21 
hours and τ1 = 2.27 hours. The nucleation event is described by  τ0, which in turn, 
corresponds to a slower rate compared to τ1. The formation of the nucleus is thought to be 
formed after several thermodynamically unfavorable steps and thus is the slow step in the 
fibrillization process.  
 
Figure 10. ThT fluorescence of Aβ 1-42 in 50 mM Na,K phosphate + 50 mM NaCl (red 
circles) and in 10 mM Na,K phosphate (blue triangles) buffers at pH 7.2 and at 37oC. Black 
lines are double exponential curve fittings of data points.  
 
 In  high ionic strength conditions ThT signal reaches a maximum at ~ 2.3 hours. The 
respective time constants are τ0 =  3.13 hours and  τ1 = 0.63 hours. Under high ionic strength 
conditions both nucleation and elongation time constants are lower than when there is less 
salt. This suggests that Aβ1-42 forms antiparallel β-sheets which are destabilized by higher 
ionic strength. There is also a significant difference in maximum intensity of ThT 
fluorescence. At higher salt concentrations there could be less fibrils. This notion can be 
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related to the low rate constants when compared to lower ionic strength.  Molecular dynamics 
simulations have suggested that ThT binds to fibril side channels.95, 118 Others have identified 
at least two binding modes for ThT on amyloid fibrils.119 This implies that subtle differences 
in binding mode  could be related to aggregate secondary structure and can cause variability 
in ThT signal intensity. 
 
Figure 11. ThT fluorescence of AβpE3-42  in  50 Na,K mM phosphate and 50 mM NaCl (red 
circles) and in 10 Na,K mM phosphate (blue triangles) buffers at pH 7.2 and 37oC.  
  
 Fibrillization kinetic experiments of AβpE3-42 are shown in (fig. 11). In this case higher 
ionic strength yields a higher ThT signal. This suggests that contrary to the unmodified 
peptide, AβpE3-42 probably forms in register parallel β-sheets, which are stabilized by the 
salt’s screening effect. Higher salt concentration screens the aligned residues with the same 




Figure 12. ThT fluorescence of the 1:1 combination in 50 mM Na,K phosphate and 50 mM 
NaCl (red circles) and in 10 mM phosphate (blue triangles) buffers at pH 7.2 and 37oC.  
 
At equimolar concentrations, low ionic strength conditions promote fibrillization when 
compared to high salt concentrations (Fig. 12).  Even though lower salt conditions promote 
faster kinetics the maximum signal is at ~12.5 hours for both conditions. Interestingly, at 
higher ionic strength there is a decrease in ThT fluorescence while the sample in low salt 





Figure 13. ThT fluorescence of the 9:1 combination in 50 mM Na,K phosphate + 50 mM 
NaCl (red circles) and in 10 mM phosphate (blue triangles) buffers at pH 7.2.  
 
 At a 9:1 Aβ1-42/AβpE3-42 (Fig. 13) combination there is no decrease in the ThT 
intensity as observed for Aβ1-42 (Fig. 10). Importantly, high ionic strength conditions result in 
higher ThT signal, as is the case for AβpE3-42. The amount of the pyroglutamylated species is 
10% of the total peptide, indicating that this behavior cannot be ascribed to an overwhelming 
AβpE3-42 concentration. This data show the prion like effect that AβpE3-42 has on Aβ 
aggregation. At low salt conditions, ThT fluorescence remains stagnant from ~7 to ~17 hours. 
Possible explanations for this are two-fold. First, the rates of fibril extension and shrinkage 
are the same, thus resulting in a zero net effect. Second, fibrils remain in a stagnant state 
where elongation does not occur. 
 The fibril shrinkage suggested by ThT assay seen in the 1:1 combination and in the 
AβpE3-42 ,  has been monitored by other groups.28, 120 The decrease in ThT signal after reaching 
a maximum has been suggested to be caused by the aggregation of additional protein on 
labeled sites and thus blocking the ThT molecule. This theory is inadequate and poorly 
explains the observed effect. If this was the case then an explanation of why this only 
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happens in some cases is required. Other have suggested that the elongated fibrils precipitate 
and escape the window being measured.120 This also lacks an explanation on why this would 
only happen occasionally.  There have been reports of fibril disassembly when there is a lack 
of monomers.28 These experiments showed that fibrils elongation and shrinkage are directly 
and inversely related to free monomer concentration, respectively. The constant ThT signal 
observed in the 9:1 and Aβ1-42 samples have been previously described by following 
fibrillization with AFM.121 Elongation occurs in small bursts when the fibril end is unblocked 




Figure 14. TEM images of Aβ1-42 (a, e, i, m), AβpE3-42 (b, f, j, n), AβpE3-42/Aβ1-42 = 1:9 (c, g, k, 
o), and AβpE3-42/Aβ1-42 = 1:1 (d, h, l, p) incubated in aqueous buffer of 50 mM NaCl and 50 
mM Na,K-phosphate (pH 7.2) for 2 h (a-d), 4 h (e-h), 12 h (i-l), and 24 h (m-p) at 37oC with 
constant stirring. The horizontal bar in each panel equals 100 nm. 
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 A high degree of variation in fibrillization kinetics and ThT fluorescent intensities 
suggest different fibril morphologies. To study the morphology of Aβ fibrils and aggregates, 
we employed TEM and AFM. TEM  measurements taken at 2,4,12  and 24 hours of 
incubation show that Aβ peptides, their 9:1 and 1:1 molar combinations fibrillize under 50 
mM phosphate and 50 mM NaCl at pH 7.2 (fig. 14). At 2 hours of incubation fibrils are 
observed for Aβ1-42 while AβpE 3-42 forms small non-fibrillar aggregates (fig. 14 a,b). 
Meanwhile, the 9:1 and 1:1 molar combinations show fibrillar structures as early as 2 hours 
(fig. 14 c,d). After four hours of incubation all samples show fibrils (fig.14 e-h). 
Additionally, At 24 hours all samples show dense entangled fibrils (fig. 14 m-p). 
Interestingly, AβpE3-42 shows bundled fibrils.    
 
Figure 15. AFM images of Aβ1-42 (A), AβpE3-42 (B), Aβ1-42/AβpE3-42  (9:1) (C), and  1:1 (D)  
combinations, incubated in aqueous buffer of 50 mM NaCl and 50 mM Na,K phosphate  (pH 
7.2) at  37oC with constant stirring. Black lines correspond to 200 nm. Red lines show second 
nucleation sites. 
 
 Further morphological studies were performed by employing AFM on Aβ peptide 
samples that were incubated for 24 hours. Fibril preparation was done using the same 
procedure as for the TEM experiments (see above). In agreement with TEM images, AFM 
images show that Aβ1−42 forms denser aggregates while AβpE3-42 shows more flexible and 
polymorphic fibrillar structures (fig. 15 a,b). Both peptides by themselves show fibrillar 
structures which have an average diameter of approximately 45 nm. When combined at a 9:1 
B A C D 
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ratio the average diameter decreases to approximately 38 nm (Fig. 15 c) Fibrils prepared 
from equimolar concentrations show an increase in size to approximately 55 nm when 
compared to the peptides by themselves.  
  Second nucleation sites are defined as extending fibrils branching out of previously 
formed fibrils and have been recently described.102 Our peptides samples show several 
second nucleation sites and examples have been labeled with red arrows. Also, fibrils extend 
from nucleation sites, which are globular aggregates present in all of the samples. As shown 
by TEM and AFM, pyroglutamated Aβ shows unique fibrillar features and also has a 
significant effect on unmodified Aβ aggregate formation. 
  Our results give mechanistic insight into previously established postulates. In mixture 
Aβ1-42 and AβpE3-42 show strong intermolecular interactions in buffer conditions. At 
equimolar concentrations AβpE3-42 has increased turn component when compared to AβpE3-42 
by itself. Varying salt concentrations affect Aβ1-42 secondary structure. At increased salt 
concentrations the turn to sheet ratio is increased. Additionally, the tertiary structure of a 1:1 
combination is salt dependent. High salt promotes an open tertiary structure, while low salt 
promotes a tight, compact structure.  
  Differences in secondary and tertiary structure shed light on disagreements seen in 
previous published fibrillization data. Low salt conditions promote Aβ1-42 fibrillization while 
inhibiting fibrillization of AβpE3-42. Importantly, at 10% AβpE3-42, the fibrillization trend 
follows that of the pyroglutamylated peptide by itself. This cannot be accredited to a majority 
of AβpE3-42 content. Our data suggest that AβpE3-42 is able to transmit structural features to 





CHAPTER FIVE: CONCLUSIONS 
 
  Our work aimed at the elucidation of the effect of AβpE3-42 on Aβ1-42 structure, 
fibrillization kinetics and final fibril morphology. It has been previously established that Aβ 
peptides are mostly α-helical in fluorinated alcohols such as HFIP. Interestingly, our data 
show that retention of the helical conformation following desiccation is dependent on total 
peptide concentration and humidity content. At 200 µM Aβ1-42 and AβpE3-42 show a prominent 
β-sheet component when dried. Conversely, at 50 µM Aβ1-42, AβpE3-42, their 9:1 and 1:1 
combinations show mostly α-helical structure after desiccation. These results carry an 
important implication. Many experiments that follow aggregation behavior claim a seedless 
and nucleus free starting point. Nevertheless, this may not be the case even when using 
methods that have been shown to break aggregates and promote monomeric form. For such 
experiments care should be taken and rigorous verification should be employed. 
 Our data suggest that initial concentrations of stocks might affect peptide structure in 
experiments and thus result in incongruences. This is especially important since oligomeric 
species and fibrils have been shown to be capable of forming through different pathways; 
presence of oligomer does not imply mandatory fibril formation.122  
 Addition of bulk D2O buffer promotes β-sheet structure in both AβpE3-42 and Aβ1-42. 
The increased presence of α-helical structure in AβpE3-42 suggests that this species does not 
fibrillize from the same starting point as Aβ1-42. Additionally, it helps explain the significant 




 Isotope edited FTIR permitted us to identify strong interactions between the peptides. 
Our data also show that mixed peptides samples in buffer show different secondary structures 
when compared to their algebraic combination.  When combined at equimolar concentrations 
the turn to sheet ratio decreases significantly for AβpE3-42. 
  Our FTIR data show that the transition to β-sheet after buffer addition occurs in an 
undetectable amount of time. Interest in the transitional states following interaction of 
monomers has increased since focus on soluble oligomeric species was established. To 
determine intermediate structures between the dried state and aqueous of AD relevant Aβ 
mixtures, we exposed the 9:1 and 1:1 combinations to nominal environmental humidity. The 
addition of nominal environmental moisture is sufficient to induce gradual conformational 
changes on Aβ peptides. AβpE3-42   at 10% total peptide concentration causes an inhibition 
of β-sheet formation by the Aβ1-42. Strikingly, At equimolar concentrations the 
pyroglutamylated peptide was able to reverse cross β-sheet formation. Our data show for the 
first time a detailed prion effect of AβpE3-42 on Aβ1-42  secondary structure. This has given 
some structural insight into previous reports that show for example, that  at  low AβpE3-42  %, 
Aβ mixtures are most toxic. Few examples exist of proteins that have been shown to be  
structurally affected by humidity.123  This implies that careful preparation in controlled 
environments is essential for Aβ samples before experiments This potentially applies to other 





 Addition of D2O saturated nitrogen gas showed dynamic changes of Aβ peptides at a 
1:1 combination. Initially, both peptides show prominent α-helical conformation; Aβ1-42 
transitions to β-sheet upon hydration. Interestingly, hydration promotes a strong turn region 
belonging to the pyrogltamylated peptide. Upon removal of windows from sample chamber, 
AβpE3-42 transitions from a β-sheet to a more unordered/helical state. Our data show that a 
higher degree of hydration does not imply a linear trend from α-helical to β-sheet as was 
hypothesized.   
 By CD we determined that upon addition of bulk aqueous buffer all samples undergo 
a structural transition towards β-sheet structures, albeit not with the same intensity. The 9:1 
combination and Aβ1-42 showed strong β-sheet signal while AβpE3-42 and the 1:1 combination 
showed a weaker signal. This corresponds to higher degree of β-sheets as intensity increases.  
 Fibrillization studies by ThT fluorescence show that ionic strength plays a 
determining role on peptide aggregation. Aβ1-42 shows higher ThT signal at lower salt 
concentrations. Conversely, AβpE3-42 has increased fibrillization at higher salt concentrations. 
These data suggest that in the case for AβpE3-42 , the peptide forms parallel β-sheets, where the 
salt helps screen like charges of  interacting residues. Interestingly, at a 9:1 combination the 
trend followed is similar to the AβpE3-42. At equimolar ratio the trend followed corresponds to 
the Aβ1-42 peptide. This shows that the effect of AβpE3-42 on Aβ1-42 does not follow 
superposition principles. The effect of salt and Aβ ratio led us to hypothesize that significant 
secondary structure differences exist in Aβ fibril seeds. As determined by FTIR at high ionic 
strength Aβ1-42 shows increased turn to sheet ratio, when compared to low salt conditions.  
Most notably, at high ionic strength, AβpE3-42 shows helical components not significantly 
present at low salt. These data show that AβpE3-42 is able to produce positive ThT signal while 
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not being in pure cross β-sheet structure. Thus expanding structural conformations ThT can 
bind to.  
 When combined at 9:1 our data show a larger turn to sheet ratio than at lower salt. 
Interestingly, higher turn to sheet ratio is not sufficient to promote ThT signal. Since Aβ1-42 
fibrillizes more readily at lower ionic strength where less turn component is present.  Further 
structural studies are necessary to determine spatial resolution of Aβ peptides and determine 
underlying factors that affect Aβ secondary structure and aggregation.  
  By employing TEM we identified distinct fibrillization pathways. At 2 hours of 
incubation Aβ1-42 shows fibril formation while AβpE3-42 shows small irregular shaped 
aggregates. The 9:1 and 1:1 combinations contain pre-fibrillar structures. After 24 hours all 
samples show fibrillar aggregates. Our data show that distinct fibrillization pathways are 
followed by Aβ and their combinations. These data help shed light on possible toxic species. 
For example, low molar content of AβpE3-42 has been shown to be hypertoxic to cultured 
neurons. Additionally, oligomers and not fibrils are currently thought to be most toxic. Our 
TEM data for the 9:1 combination show lack of mature fibrils after 4 hours of incubation. 
These data suggest that small oligomers cause neuronal death and that possibly fibrils act as a 
rescue mechanism and are not the main toxic entities. 
 AFM data further elucidated fibril morphology. At a 1:1 combination the fibrils have 
fibril morphology that is intermediate between Aβ1-42 and AβpE3-42. Nucleation and second 
nucleation sites can be observed, giving indication of fibril initial elongation sites and 





 Non fibrillar oligomeric species are thought to be the toxic entities in AD.  Strikingly, 
our studies confirm that not only does ionic strength affect Aβ secondary structure but also 
fibril stability. At equimolar concentrations, physiologically relevant ionic strength  ThT 
studies, show that fibrils disassemble before 24 hours of incubation, while ThT fluorescence 
does not decrease at low salt. Further toxicity studies are needed to determine if this loss in 
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